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 Runx2 is a transcription factor required for bone formation and osteoblastic 
differentiation during normal development and is implicated in metastatic disease during 
breast cancer progression. Runx2 is highly expressed in many metastatic breast cancers 
and breast cancer cell lines Knockdown of Runx2 in various breast cancer cell lines 
restores epithelial characteristics and reduces proliferation, migration, and invasion. 
However, the role of Runx2 in breast cancer progression from early to late stages is not 
well understood. The MCF10A derived breast cancer progression model provides the 
opportunity to study the role of Runx2 in a series of cell lines that progress from nearly 
normal, with low Runx2 levels, to highly metastatic and aggressive, with much higher 
Runx2 levels. To address if removal of Runx2 affects gene expression and what pathways 
it may influence, specifically focused on breast cancer progression, we knocked down 
Runx2 using an shRNA lentivirus. Depletion of Runx2 inhibits the expression of 
mesenchymal markers including N-cadherin, Fibronectin, and Vimentin. Despite this 
finding, functional characteristics including proliferation, migration, and invasion were 
minimally affected. Possible reasons for the difference in results compared to other cell 
systems are discussed. As an alternative approach, we have generated stable, inducible 
cell lines using CRISPRi dCas9-KRAB to target Runx2 and in the future will investigate 
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CHAPTER 1: INTRODUCTION 
1.1 Runx 
 Runt-related transcription factors, or Runx, were identified in three different 
organisms. First, in Drosophila melanogaster as the segmentation gene Runt, then in 
acute myeloid leukemia patients as a chromosome translocation, and lastly in the 
polyoma-virus enhancer binding protein 2 (Ito et al., 2015). Mammals have three Runx 
proteins, Runx1, Runx2, and Runx3 that are expressed in a tissue-dependent manner (Ito 
et al., 2015). The three closely related genes likely emerged from a triplication mutation, 
implied by a 128 amino acid conserved runt DNA binding domain (Blyth, Cameron, & 
Neil, 2005). Each Runx gene is involved in a developmental pathway and is also 
associated with different types of cancer. Runx1 mutations are associated with human 
leukemia, whereas the overexpression of Runx2 in breast and prostate cancer cells leads 
to metastasis to bone, and inactivation of Runx3 contributes to cancer pathogenesis and is 
common in human gastric carcinomas (Blyth et al., 2005; Ito et al., 2015). Runx1 has a 
role in hematopoiesis, Runx2 in bone development, and Runx3 in 
gastrointestinal/neuronal development (Owens et al., 2014).  
 Runx proteins share common features, including a common DNA binding domain 
called runt, as well as two promoters (Figure 1) (Levanon & Groner, 2004; Vimalraj, 
Arumugam, Miranda, & Selvamurugan, 2015). They all bind the same DNA motif and 
use common transcriptional modulators (Levanon & Groner, 2004). Runx factors form a 
heterodimer with a co-transcription factor, CBFβ, which enables the recognition of the 
consensus sequence PyGPyGGTPy in the Runx targets (Vimalraj et al., 2015). Also 
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conserved is a CpG island at the C-terminus of each of the Runx genes (Levanon & 
Groner, 2004). Modifications to these CpG islands could affect the activities of the Runx 
genes and their expression. For example, a CpG island in Runx3 promoter 2 is 
hypermethylated in gastric cancer, but in promoter 1, where another CpG island is 
located, lack of methylation occurs in T cell lymphomas (Levanon & Groner, 2004).  
In normal cells, Runx proteins are conserved regulators of cell fate. Runx factors 
contribute to regulation of gene expression as part of a core binding factor (CBF) 
complex. This Runx2-CBF complex regulates expression of many genes, including those 
that are related to cancer in both tumor suppressor and oncogenic pathways (Blyth et al., 
2005).  
 Runx1 acts as a tumor suppressor in breast cancer (Chimge & Frenkel, 2013). It is 
the predominant Runx protein expressed in breast epithelial cells and was found to be 
mutated in many different patient samples in various breast cancer studies (Chimge & 
Frenkel, 2013). Loss of Runx1 in MCF7 breast cancer cells and MCF10A normal-like 
breast epithelial cells promotes an epithelial to mesenchymal transition (EMT) (Hong et 
al., 2017). EMT is an important event in cancer progression, allowing cancer cells to 
develop metastatic potential (Hong et al., 2017). One mechanism through which this 
occurs is that Runx1 directly upregulates the epithelial marker, E-cadherin, preventing 
the cells from losing epithelial characteristics. Further evidence to support this result is 
that upon depletion of Runx1 in MCF10A cells, E-cadherin levels decrease (Hong et al., 
2017).   
Runx3 appears to act as a tumor suppressor in some cancers, as overexpression of 
Runx3 results in the inhibition of growth in carcinoma cell lines (Blyth et al., 2005). In 
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patient samples, Runx3 levels seem to decrease as breast cancer progresses and 
furthermore, higher levels of Runx3 are associated with a more favorable prognosis 
(Chimge & Frenkel, 2013). One cause of Runx3 deregulation in breast cancer could be 
estrogen signaling. There is a positive relationship between estrogen levels and risk of 
breast cancer (Colditz, 1998). Treatment with Estradiol, a type of estrogen, results in 
hypermethylation of the promoter, preventing transcription of Runx3 (Chimge & Frenkel, 
2013). 
Runx2 has two promoters, which leads to the production of two isoforms with 521 
and 507 amino acids, respectively (Vimalraj et al., 2015). Runx2 is required for normal 
mammary alveolar development during late pregnancy and for the specification of 
alveolar cell maturation (Owens et al., 2014). It also functions as a regulator of 
osteoblastic differentiation, skeletal morphogenesis, and stem cell differentiation into 
osteogenic lineages (Vimalraj et al., 2015). Runx2 levels have been shown to remain 
constant through adulthood and early to mid-pregnancy in mice mammary tissues, 
however levels drop significantly towards the end of pregnancy and throughout lactation 
(Owens et al., 2014).  
Runx2 is also required for bone formation, and Runx2 knockout mice die at birth 
(Choi et al., 2001). Deletions at the C terminus are particularly detrimental; causing mice 
with this c terminal deletion to die in utero, versus Runx2 null mice, which die at birth 
(Choi et al., 2001). Significant development problems occur when even one copy of 
Runx2 is missing due to haploinsufficiency (Choi et al., 2001).  
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Figure 1: Homology between Runx1, 2, and 3 (Ito et al., 2015). Each protein has a Runt 
domain, which is the DNA binding domain, an activation domain (AD), an inhibitory domain 
(ID), and a VWRPY domain, which interacts with the co-repressors. 
 
Runx2 is involved in breast cancer metastasis. In in vitro studies, Runx2 has 
proven to be a tumor promoter in most cases. It upregulates genes involved in cellular 
movement and cytoskeleton remodeling (Baniwal et al., 2010). Runx2 also activates 
matrix metalloproteases (MMP) 9 and 13, osteopontin, vascular endothelial growth factor 
(VEGF), and the bone resorbing factors parathyroid hormone-related protein (PTHrP) 
and interleukin-8 (IL-8) in MDA-MB-231 and MCF7 breast cancer cell lines (Akech et 
al., 2010). Runx2 overexpression has been shown to cause aberrant proliferation and 
inhibition of apoptosis in normal mammary epithelial cells (Owens et al., 2014). In 
prostate cancer, Runx2 prevents apoptosis by stimulating the expression of Bcl2 and 
Survivin (Chimge & Frenkel, 2013). Overexpression of Runx2 also drives EMT-like 
changes in normal mammary epithelial cells and may also have a role in breast cancer 
metastasis to bone (Owens et al., 2014). Studies have shown that deletion of Runx2 in 
mammary epithelial cells in mice is associated with increased survival and reduced cell 
proliferation of basal breast cancer cells (Owens et al., 2014).  
	 	5	
 
1.2 Epithelial to Mesenchymal Transition 
 The epithelial to mesenchymal transition occurs normally during embryogenesis 
and is a process in which epithelial cells change their shape and behavior (Mendez, 
Kojima, & Goldman, 2010). Epithelial cells lose polarity and attachment to neighboring 
cells, as well as basement membranes, and become flattened and elongated and change 
the composition of cytoskeletal components, upregulating vimentin and N-cadherin, 
while down regulating other types of cytoskeletal proteins such as E-cadherin (Mendez et 
al., 2010). These changes allow the cell to become motile and acquire an invasive 
phenotype (Lamouille, Xu, & Derynck, 2014). EMT also occurs during wound healing 
and tumorigenesis (Lamouille et al., 2014). The first step is usually the loss of cell-cell 
junctions, which normally help with the barrier function of epithelial cells. Next is the 
reorganization of the actin cytoskeleton to allow for elongation and direction-specific 
movement. Projections also develop and protrude out of the cell, acting as sensory organs 
(Lamouille et al., 2014). Other actin-rich protrusions produce chemicals that help degrade 
the extracellular matrix. Loss of normal cell polarity and the development of front-rear 
polarity also occurs at this point (Lamouille et al., 2014). Next, changes in protein 
expression are elicited. E-cadherin, a typical epithelial marker is downregulated and N-
cadherin, a mesenchymal protein, is upregulated (Lamouille et al., 2014). Various 
transcription factors aside from Runx2 including SNAIL, TWIST, and ZEB are also 
involved in the control of expression of genes that regulate the EMT process (Lamouille 
et al., 2014).  
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 Tumor cell metastasis occurs as EMT is completed and cells become detached 
from the original tumor. MMP 1 is expressed and is necessary for tumor cell invasion 
into bone, because it is a collagenase, and can dissolve bone (Kozlow & Guise, 2005). 
Tumor cells must extravasate from the original tumor site and enter systemic circulation 
(Kozlow & Guise, 2005). This can be accomplished by making new blood vessels in a 
process known as angiogenesis (Kozlow & Guise, 2005). Bone secretes chemicals that 
attract the tumor cells, such as SDF-1, which binds to the CXCR4 receptor on the tumor 
cells. Tumor cells then become trapped in bone marrow and must reach and adhere to the 
endosteal surface in order to survive (Kozlow & Guise, 2005).  
Figure 2: Genes controlled by Runx2 involved in EMT. Primary tumor cells undergo 
changes in gene expression profiles to be able to metastasize and grow in bone. Factors 
including VEGF, MMPs, and PTHrP mediate some of the changes necessary for cellular 
processes involved in metastatic transformation, and are regulated directly by Runx2 (Pratap 
et al., 2006). 
1.3 Role of Runx2 in EMT and Metastasis 
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 Runx2 is a transcription factor that regulates many genes that control the EMT 
process (Figure 2) (Pratap et al., 2006). Runx2 is implicated in breast cancer metastasis to 
bone causing osteolytic disease. In vitro experiments show that knockdown of Runx2 
inhibits the ability of the cancer cells to interact with bone (Barnes et al., 2004). 
Furthermore, introducing mutant Runx2 in MDA-MB-231 breast cancer cells has been 
shown to cause a reversion to more normal breast tissue, and reduced proliferation 
(Pratap et al., 2009). Downstream targets of Runx2 have been shown to increase within 
many breast cancer cell lines where Runx2 is upregulated (Pratap et al., 2005). VEGF is a 
proangiogenic factor and is overexpressed during EMT (Gonzalez-Moreno et al., 2010). 
In prostate cancer cell lines, overexpression of VEGF leads to increased vascularization 
and tumorigenic capabilities (Gonzalez-Moreno et al., 2010). Other targets of Runx2 
include epithelial markers such as E-cadherin, which decreases during EMT, and 
mesenchymal markers such as N-cadherin and Vimentin, which increase during EMT 
(Gonzalez-Moreno et al., 2010). N-cadherin allows cells to seek other cells expressing N-
cadherin and promotes weaker interactions than does E-cadherin, allowing cells to remain 
motile and have invasive properties (Lamouille et al., 2014). Vimentin is also 
upregulated, while another type of intermediate filament, cytokeratin, is downregulated. 
Vimentin directs E-cadherin towards the cell membrane and interacts with motor proteins 
to help with cell motility (Lamouille et al., 2014). Expression or repression of various 
integrins that allow the cell to receive signals occurs during EMT, concordantly with 
MMP2 and 9 expression. MMP2 and 9 assist with extracellular matrix degradation, 
invasion, and further loss of cell-cell junctions (Lamouille et al., 2014). These changes 
allow the cell to be able to migrate from its original location and survive in a new 
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location. As shown in Figure 2, Runx2 is a direct mediator of many of the proteins 
involved in EMT, and the increased Runx2 levels in breast cancer cells compared to 
normal breast epithelial cells help to activate EMT to promote breast cancer progression 
(Pratap et al., 2006).  
 
1.4 Breast Cancer Prevalence and Role of Runx2 in Metastasis 
Breast cancer is the most commonly diagnosed cancer in women and the second 
leading cause of cancer-related deaths in women (DeSantis, Ma, Bryan, & Jemal, 2014). 
Metastasis of breast cancer cells is the cause of the most deaths associated with breast 
cancer because after breast cancer metastasizes to bone, it becomes incurable (Kozlow & 
Guise, 2005; Taylor, Sossey-Alaoui, Thompson, Danielpour, & Schiemann, 2013). In 
patients with advanced stages of breast cancer, 80% develop bone metastases, causing 
hypercalcemia, bone pain and fractures, and increased morbidity and mortality (Kozlow 
& Guise, 2005). Five-year survival drops from 98% to 23% when breast cancer becomes 
metastatic (Taylor et al., 2013). Another side effect of bone metastasis is cachexia, or 
muscle and fat wasting, which leads to skeletal related problems and events, and limits 2-
year survival to 50% (Kozlow & Guise, 2005). Bone marrow suppression leading to 
leukopenia can also occur (Kozlow & Guise, 2005).  
Certain cancers have a tendency to metastasize to bone, including breast and 
prostate cancer (Guise, 2002). When metastasis to bone does occur, the survival of the 
cancer cells in the bone is mediated by cancer cell-bone cell interactions (Guise, 2002).  
These interactions alter the bone microenvironment, allowing the cancer cell to survive, 
and creating what is known as the “vicious cycle” (Guise, 2002). The vicious cycle 
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occurs by osteoclast-mediated osteolytic bone destruction. PTHrP, the expression of 
which is controlled by Runx2, activates osteoclasts and results in increased osteoclast 
bone resorbing activities. Treatment with anti-PTHrP antibody decreases osteolytic bone 
destruction and inhibits the formation of bone metastases (Guise, 2002). TGFβ is stored 
in the bone matrix and is released upon osteoclast bone resorption. TGFβ also induces 
cancer cells to produce PTHrP. In breast cancer cell lines with mutant TGFβ receptors, 
PTHrP levels were decreased and bone metastasis growth slowed (Guise, 2002). PTHrP 
release can also be induced by high levels of extracellular calcium, which occurs during 
the vicious cycle (Guise, 2002). PTHrP also causes the increased expression of RANKL 
on osteoblasts, which is the activating receptor for osteoclasts (Kozlow & Guise, 2005).  
Although the role of Runx2 in metastasis of breast cancer has been studied, the 
mechanism of regulation remains unclear, especially in early stage breast cancer. The 
mechanisms by which Runx2 enables metastasis to bone are important in understanding 
how breast cancer cells are able to survive in bone (Pratap et al., 2006). An increase in 
Runx2 expression allows breast cancer cells to behave more like osteoblasts, which leads 
to osteomimicry (Barnes et al., 2004). Osteomimicry is what helps breast cancer cells 
home to bone, making Runx2 a potential target for therapy (Barnes et al., 2004).  
 
1.5 Breast Cancer Progression Model Cell Lines 
The MCF10A cell line is a normal-like breast epithelial cell line that was 
transformed to generate a progression model to study breast cancers. The MCF10A 
parental cell line was isolated from benign breast tissue from a woman with fibrocystic 
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disease (Santner et al., 2001). MCF10A cells are considered normal because they do not 
invade or form tumors in immunodeficient mice (So, 2014).  
MCF10A cells were transduced with T24 c-Ha-ras oncogene and then passaged 
through a mouse, generating the MCF10AT cells. The MCF10AT cells persist in small 
nodules and periodically form carcinomas when injected into mice (Dawson, Wolman, 
Tait, Heppner, & Miller, 1996). Cells from one of these carcinomas were grown in 
culture, generating the MCF10AT1 cell line (Dawson et al., 1996). MCF10AT1 cells are 
non-metastatic, premalignant cells (Santner et al., 2001).  
 MCF10CA1a are fully malignant, metastatic cells that are derived from 
MCF10AT cells (Santner et al., 2001). MCF10CA1a cells are the most aggressive cell 
line in the MCF10A series, with 100% transformation capacity in immunodeficient mice 
(Santner et al., 2001) (So, 2014). To develop the cell line, MCF10AT cells were injected 
into nude-beige mice. Cells that went on to produce carcinomas were cultured and 
cloned. One of the clones was used to create a second-generation xenograft. 
Subsequently, third and fourth generation tumors were created. These tumors were 
digested and then the cells injected into mice. The resulting cells that were isolated 
constitute the MCF10CA1a cell line and rapidly form tumors 100% of the time upon 
injection into mice, without evidence of a precursor stage (Santner et al., 2001). These 
three cell lines, MCF10A, MCF10AT1, and MCF10CA1a serve as a model to study 
various aspects in the biology of breast cancer progression (Santner et al., 2001). Runx2 











Figure 3: Runx2 mRNA levels in the MCF10A series. The MCF10A series were subject to 
global RNA sequencing using next generation sequencing. There is an increase in the Runx2 
levels, as shown by the Normalized HTSeq Counts, as cells go from the normal MCF10A 
cells to the cancerous MCF10AT1 and MCF10CA1a cells. 
 
1.6 Experimental Strategy 
We used MCF10CA1a and MCF10AT1 cell lines to investigate the effects of 
Runx2 knockdown using both CRISPRi and short hairpin RNA-Runx2 systems. Stable 
cell lines expressing the shRunx2 and the dCas9/guide RNA were generated. In the 
shRunx2 cells, GFP was used to select for cells with similar, medium amounts of shRNA 
expression. For CRISPRi, Geneticin, also known as G418, and Puromycin were used as a 
selection for integration of the dCas9 and guide RNAs, respectively. Using these stable 
cell lines, levels of Runx2 itself and its targets, as mentioned by Pratap et. al, 2005, 
including osteocalcin, osteopontin, PTHrP, VEGF, IL-8, Survivin, E-cadherin, Vimentin, 
and N-cadherin were measured to characterize these Runx2 knockdown cells via real 
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time PCR and Western blotting. Western blotting was used as a definitive method to 
check Runx2 knockdown efficiency and confirm the effect of Runx2 knockdown on the 
proteins listed above. RNA sequencing was performed on these cells to investigate global 
changes in gene expression.  
 Due to the known role of Runx2 in regulating invasion and migration in MDA-
MB-231 cells (Pratap et al., 2009), functional assays were performed that measure cell 
proliferation, migration, and invasion. We performed a proliferation assay to measure cell 
proliferation each day, a scratch (wound healing) assay to assess motility of cells, as well 
cell invasion and migration assays using Transwell chambers with or without Matrigel. 
These assays were done in both the MCF10CA1a and MCF10AT1 cells expressing 
shRunx2, and the control cells were infected with empty vector (EV) plasmid containing 
lentivirus.  
 Although the role of Runx2 in breast cancer metastasis has been studied, the role 
of Runx2 in early cancer events remains unclear. One of the aims of our project is to 
begin to understand the consequences of Runx2 knockdown on Runx2 target genes in 
less aggressive breast cancers, represented by MCF10AT1. The MCF10A cell lines allow 
us to study the global effects of Runx2 knockdown in both aggressive (MCF10CA1a) and 







CHAPTER 2: MATERIALS AND METHODS 
2.1 Cell Culture 
 MCF10CA1a cells were maintained in DMEM (Corning CellGro), 5% horse 
serum (Gibco 16050), 1% Penicillin streptomycin (Gibco Life Technologies), and 1% L-
glutamine (Gibco Life Technologies) at 37°C. MCF10AT1 cells were maintained in 
DMEM (Corning CellGro), 5% horse serum (Gibco 16050), 1% Penicillin streptomycin 
(Gibco Life Technologies), 1% L-glutamine (Gibco Life Technologies) 10 µg/mL Human 
insulin (Sigma I-1882), 20 ng/mL hEGF (Gibco Life Technologies), 100 ng/mL Cholera 
Toxin (Sigma C-8052), and 0.5 µg/mL Hydrocortisone (Sigma H-0888) at 37 °C. To 
subculture the cells, 0.25% trypsin was diluted 1:10, and added to cells for 20 minutes, 
and cells were replated 1:10.  
 HEK-293-FT cells were grown in DMEM (Corning CellGro), 10% Fetal Bovine 
Serum (Atlanta), 1% Penicillin streptomycin, 1% L-glutamine, 1% MEM Non-essential 
amino acid solution (Gibco Life Technologies), and 500 µg/mL Geneticin (Sigma-
Aldrich).  
 To freeze cells, Bambanker Cryopreservation Medium (Wako Pure Chemical 
302-14681) was used to resuspend pelleted cells at a density between 2 and 10 million 
cells per mL. One milliliter of solution was dispensed into each cryovial. Cryovials were 
frozen at -80°C in a container filled with isopropanol and stored at -80°C.  
  
2.2 Lentiviral Transduction 
 Lentiviruses are an effective vector for altering gene expression in mammalian 
cells. Lentiviruses can be used to carry shRNA into cells in order to silence gene 
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expression, in a process of posttranscriptional gene modification known as RNA 
interference (Van den Haute, Eggermont, Nuttin, Debyser, & Baekelandt, 2003). RNA 
interference was designed as a faster and cheaper alternative to genetic knockouts that 
could be used in a larger variety of organisms (Stewart et al., 2003). The lentivirus is 
used to deliver shRNA that will knock down expression of a specific gene (Rubinson et 
al., 2003). When the lentivirus enters the cell, the shRNAs are cleaved by Dicer, 
generating small dsRNAs that are able to induce knockdown of the target gene (Stewart 
et al., 2003). One advantage of the lentiviral system is that it can be used in non-dividing 
cells (Stewart et al., 2003). Another advantage is that silencing of the genes delivered by 
lentiviral vectors does not occur during development, meaning embryonic stem cells can 
be transduced (Rubinson et al., 2003). The shRNA can also be selected for to generate 
and maintain stable cell lines (Rubinson et al., 2003).  
 Stable cell lines expressing empty vector or shRunx2 were generated as follows: 
MCF10CA1a cells, passage 34, were infected with Runx2 PLVTHM Sh 4/4 lentivirus or 
PwtsI empty vector (EV) (Figure 4), as described in Afzal et al., 2005. PLVTHM vector 
used in this study co-expresses green fluorescent protein (GFP) along with the shRNA or 
EV, and can be used as a selection marker. Cells were plated at 3x105 cells/well on a 6-
well plate in 2 mL of the MCF10CA1a or MCF10AT1 media described above. Cells 
were cultured for 24 hours to about 40% confluency before 100 or 150 µL of virus with 4 
µg/mL polybrene were added to each well. After 24 hours the medium was replaced.  
Forty-eight hours after the initial plating, cells were trypsinized and split into 100 mm 
plates. MCF10AT1 cells were infected the same way; however, it is necessary to plate 
these cells at a lower initial density since they grow much more rapidly. This infection 
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was done in three separate instances for both MCF10CA1a and MCF10AT1 cell lines to 
create three biological replicates per line. After passage 3 post-infection, live cells were 
sorted using flow cytometry, as described in the next section. 
 
 
Figure 4: Lentiviral vector used for generation of shRNA against Runx2 (Wiznerowicz & Trono, 
2003).  The EV is the same vector without the shRNA against Runx2. 
 
2.3 Flow Cytometry for Live Cell Sorting 
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 After infection, cells were sorted for GFP using Fluorescence-Activated Cell 
Sorting (FACS). FACS is a type of flow cytometry that analyzes and sorts live cells 
based on expression of fluorescently tagged proteins (Figure 5) (Herzenberg et al., 2002). 
Cells were collected via trypsinization, washed with PBS, filtered through 100 micron 
cell strainers to avoid clumps, and resuspended in 1% horse serum DMEM. Cells were 
brought to the University of Vermont Flow Cytometry and Cell Sorting Facility where 
they underwent a one-way sort to select cells expressing medium levels of GFP on a BD 
FACS AriaII machine. The BD FACS AriaII can perform up to four-way sorting, detect 
up to 13 fluorescent signals, as well as forward and side scatter, at three different nozzle 
pressures. Only the cells expressing GFP at intermediate levels were collected, and the 
high and low expressing cells were not used (Figure 5). To determine optimal GFP 
concentration for cell sorting, we first collected both high and low GFP expressing cells. 
We observed broad variation and inconsistent Runx2 knockdown within samples; 
therefore we decided to select cells expressing medium levels of GFP that showed 
minimal variability. A purity check was performed on the samples after sorting to ensure 
that only the medium GFP expressing cells were collected. After collection, cells were 












Figure 5: Cell Sorting and Gating Strategy after transduction with lentivirus. The SSC 
and FSC, or side scatter and forward scatter gates show that population of cells based on size 
parameters. In these gates, cells are distinguished from debris based on size. The GFP graph 
shows the population of cells we collected based on intermediate GFP expression. 
 
2.4 CRISPR/Cas9 System 
 Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) is a 
bacterial immune system that can be utilized for genome engineering. There are two 
critical components of the CRIPSR system, the guide RNA (gRNA), which binds to a 
specific sequence and helps to localize the second component, CRISPR-associated 
endonuclease, Cas9 (Larson et al., 2013). CRIPSR interference, or CRIPSRi uses a 
catalytically dead version of Cas9, lacking endonuclease activity, called dCas9 with an 
GFP	
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attached KRAB repressor domain (Larson et al., 2013). The dCas9 gets stuck on the 
mRNA while the KRAB domain represses translation (Larson et al., 2013). CRISPRi has 
many advantages over traditional gene editing in that it is inducible/reversible and is 
simple and inexpensive because it requires gRNA sequences to be only 20 nucleotides 
long (Larson et al., 2013). Various sites within the gene can also be targeted with dCas9, 
allowing for specific regulation of gene expression so that translation or translation 
initiation can be effected (Larson et al., 2013). Off-target effects as seen with RNAi and 
the expensive nature of Zinc-finger proteins are mostly avoided when using CRISPRi 
(Larson et al., 2013). Limitations include the necessity for a protospacer adjacent motif 
(PAM) sequence of NGG when targeting the dCas9 to a location in the genome. There 
are, however, other PAM sequences that are becoming available for use with the 
CRISPRi system (Larson et al., 2013). Off target effects can be seen in large genomes 
due to the short nature of the CRISPRi targeting, but longer PAMs could prevent this 
from occurring (Larson et al., 2013).  
 Guide RNAs tagging both promoters of the RUNX2 gene were designed using 
Benchling software (Figure 7) (https://benchling.com). Primers were annealed using 
ligation buffer and T4 Polynucleotide Kinase (New England Biolabs). Primers were 
diluted from 100µM 1:250. Primers were then ligated into the LentiGuide-Puro backbone 
(Addgene) with FastDigest reagents (Thermo Fisher). DNA was then treated with 
PlasmidSafe Buffer and DNase (Illumina). Plasmids were then transformed into One 
Shot™ Stbl3™ Chemically Competent E. coli.  Colonies were selected and grown in LB-
Amp broth overnight. Minipreps were performed on these colonies using the Zyppy™ 
Plasmid Miniprep kit (Zymo Research), and DNA was sequenced. Selected DNA was 
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transformed into One Shot™ Stbl3™ Chemically Competent E. coli (Invitrogen) and 
resequenced to ensure recombination did not occur. Midi preps were prepared from these 
cultures and DNA was isolated using the ZymoPURE™ Plasmid Midiprep kit (Zymo 
Research).  
 Stable cell lines expressing dCAS9-KRAB were generated. A lentiviral mediated 
integration system was used to stably express dCAS9-KRAB/guide RNAs in MCF10AT1 
and MCF10CA1a cells. Virus production for Lentiviruses expressing dCas9 or guides is 
explained below (Figure 7). HEK-293-FT cells were plated in 100 mm plates at 2x106 
cells/plate. After 24 hours, cells were transfected with 10 µg TRE-dCAS9-KRAB, or 
guide RNAs, an enveloping plasmid PMD2-G, and a packaging plasmid pSPAX2 at a 
2:1:1 ratio. DNA and X-tremeGENE (Sigma-Aldrich) were mixed in a 1:1 ratio and 
incubated at room temperature for 30 minutes in serum free medium.  The DNA/X-
tremeGENE solution was then added to the HEK-293-FT cells in 6 mL of complete 
medium. Cells were incubated 18 hours, and medium was removed. Ten milliliters of 
fresh complete media was added and virus collected after 24 and 48 hours. pLenti CMV-
GFP 736-1 was used as a control to visualize the efficiency of the transfection. Lentivirus 
was concentrated to 10X using Lenti-X™ Concentrator Protocol (Clontech).  
 Next, MCF10AT1 and MCF10CA1a were plated at 5x105 cells per well in a 6-
well plate. The next day, 150 µL concentrated dCas9-KRAB virus was added to the cells 
along with 4µg/mL polybrene. After 24 hours, medium was changed to G418 (Sigma-
Aldrich #4727878001) containing medium at a concentration of 1500 µg/mL (http://cell-
lines.toku-e.com/Antibiotics_14.html). Medium was changed every 3-4 days for three 
weeks until cells began to grow in colonies. These cells were harvested and induced for 
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dcas9 expression by induction every 24 hours with 1.5 µg/mL doxycycline for 24, 48, 
and 72 hours total (Figure 6). Samples were prepared in lysis buffer (see below), run in 
an 8.5% acrylamide gel, and stained overnight in Runx2 (1:1000; Cell Signaling). To 
detect dCas9, a 6% acrylamide gel was used, with overnight transfer at 30 Volts and 






Figure 6: Incorporation and inducibility of dCas9 in MCF10AT1 and MCF10CA1a. A. Nested PCR 
of neomycin to check for incorporation of dCAS9 plasmid into the genome. B. Western blot of dCas9 
expression after induction with doxycycline at hour 0.  
 
 After checking for dCas9 integration and induction using the primers forward 
primer Neo F-CGTTGGCTACCCGTGATATT and the reverse primer WPRE R-
CATAGCGTAAAAGGAGCAACA for nested PCR (Figure 6), dCas9 expressing 
MCF10AT1 and MCF10CA1a were transduced with guide RNAs for promoter 1, 
promoter 2, and promoters 1 and 2 together. Infected cells were selected after 24 hours 
using 0.5/1 µg/mL and 2 µg/mL puromycin for MCF10CA1a and MCF10AT1, 























Figure 7: Genomic position of Guide RNAs to target Runx2 gene. The guide at promoter 1 binds to the 
region of the gene just before Exon 1, and the guide at promoter 2 binds at the beginning of Exon 2. 
 
2.5 RNA Extraction and cDNA preparation 
 Once cells reached confluence, cells were scraped off a 100 mm plate and the cell 
pellets were stored at -80 °C until RNA extraction. RNA was extracted from pelleted 
cells using the Qiagen RNeasy Plus Mini Kit according to the manufacture’s protocol. 
RNA was stored at -80 °C until cDNA was made using SuperScript III First Strand 
Synthesis System for RT-PCR (Invitrogen). RNA samples were sent to the UVM 
Advanced Genome Technologies Core for RNA quality analysis (Figure 8). RNA 
















Figure 8: RNA Integrity Example. RNA integrity number (RIN) is 10, which is the best score. 
 
2.6 Quantitative Real-Time Polymerase Chain Reaction (q-RT-PCR) 
 cDNA was made as described above. SYBR green (BioRad) was used along with 
the following primers: 
Table 1: Primer Sequences used in qPCR 
Primer Forward Primer sequence 5’-3’ Reverse Primer Sequence 5’-3’ 
hGAPDH ATGTTCGTCATGGGTGTGAA TGTGGTCATGAGTCCTTCCA 
hRunx2 CAGCCCCAACTTCCTGTG CCGGAGCTCAGCAGAATAAT 
hRunx1 GTCGAAGTGGAAGAGGGAAA CCGATGTCTTCGAGGTTCTC 
hVEGF CCTTGCTGCTCTACCTCCAC CCATGAACTTCACCACTTCG 
hIL-8 GTGCAGTTTTGCCAAGGAGT CTCTGCACCCAGTTTTCCTT 
hVimentin GACGCCATCAACACCGAGTT CTTTGTCGTTGGTTAGCTGGT 
hE-cadherin CGAGAGCTACACGTTCACGG GGGTGTCGAGGGAAAAATAGG 
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hN-cadherin TGCGGTACAGTGTAACTGGG GAAACCGGGCTATCTGCTCG 
hFibronectin CGGTGGCTGTCAGTCAAAG AAACCTCGGCTTCCTCCATAA 
hITGA3 TGTGGCTTGGAGTGACTGTG TCATTGCCTCGCACGTAGC 
hITGB1 CCTACTTCTGCACGATGTGATG CCTTTGCTACGGTTGGTTACATT 
hSurvivin AGGACCACCGCATCTCTACAT AAGTCTGGCTCGTTCTCAGTG 
 
q-RT-PCR was performed using Viia 7 Thermal cycler from Applied Biosystems (Life 
Technologies). The thermal cycling protocol was performed using a fast block, with 
denaturation at 95°C for 1 sec and annealing/extension at 60°C for 20 sec for 40 cycles. 
The melting curve analysis and polymerase activation and DNA denaturation were 
carried out at 95°C for 1 sec, 60°C for 1 min, and 95°C for 15 sec. Calculations were 
based on normalization to the control, GAPDH, and then again to the EV, giving delta 
delta threshold cycle (ddCT) values. Based on dCT values, the relative expression was 
calculated along with the positive and negative difference for error. All experiments were 
carried out on three independent biological replicates, with three technical replicates 
each. Statistical analysis was performed using a two-tailed, paired T-test.  
 
2.7 Western Blotting 
 Protein isolation was done using direct lysis buffer. Cells were harvested via 
scraping or trypsinization from 100 mm plates when they reached 90% confluence. 
Direct lysis buffer containing 2 M urea, 10 mM DTT, 10% glycerol, 1M Tris-HCL pH 
6.8, 2% SDS, 1 mg bromophenol blue, 250 µL protease inhibitor (Roche Diagnostics), 
and 5 µL MG132 protease inhibitor (Calbiochem) was added to cell pellets. Samples 
were boiled for 10 minutes at 100°C and then centrifuged at 21,000 x g for 2 minutes.  
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The protein lysates were loaded on an 8.5% acrylamide gel and run at 80 V for 20 
minutes and 120 V for 1 hour. Transfer buffer (25 mM Tris, 192 mM glycine, 20% 
methanol, and water) was used with a submerged wet transfer system (BioRad) and 
performed at constant 300 mAmps for 2 hours. The PVDF membrane was incubated for 
one hour at room temperature in 5% milk/tris buffered saline (TBS), then in primary 
antibody in 5% milk/TBS at 4°C overnight, or for 30 minutes at room temperature, 
depending on the antibody. Membranes were washed with TBST for 20, 10, 10, 10 
minutes before the appropriate secondary antibody was added at 1:2000 in 5% milk/TBS 
with 0.1% Tween for one hour at room temperature. Membranes were washed 10, 10, 10, 
5 minutes before a 1-minute detection with Clarity Western ECL Substrate (Biorad). 
Antibodies used: Runx2 (Cell Signaling) at 1:1000, B-actin (Cell Signaling) at 1:3000, 
Runx1 (Cell Signaling) at 1:1000, E-cadherin (Cell Signaling) at 1:1000, N-cadherin 
(Cell Signaling) at 1:1000, and Vimentin (Santa Cruz Biotechnology) at 1:1000. Western 
Blots were quantified using Image Lab Software (Biorad) densitometry tool.  
 
2.8 Cellular Characterization with Functional Assays 
2.8.1 Cell Proliferation Assay 
 Proliferation assays are useful in determining cell proliferation rate (Vander 
Heiden, Cantley, & Thompson, 2009). When cells become cancerous, the proliferation 
rate often increases substantially because genes are upregulated that promote the 
constitutive uptake and metabolism of nutrients (Vander Heiden et al., 2009). We wanted 
to understand if knocking down Runx2 changed the proliferation rate in our cells.  
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 Cells were plated on a 6-well plate at 35,000 cells per well, in triplicate. Cells 
were counted daily for four days. Untreated, shRUNX2, and EV cells were counted for 
both MCF10CA1a and MCF10AT1 from three independent infections.  
 
2.8.2 Wound Healing (Scratch) Cell Motility Assay 
 A wound healing assay by making a scratch on a confluent cell culture plate is an 
inexpensive and simple assay to measure cell migration/motility (C. C. Liang, Park, & 
Guan, 2007). Cells are grown to confluence in monolayer culture before a scratch is made 
and images are captured at regular time points. This method is advantageous because it 
mimics migration in vivo to some extent (P. Liang, Averboukh, Keyomarsi, Sager, & 
Pardee, 1992). Cells were plated at 0.5x106 cells/well (MCF10CA1a), and 0.3X106 
cells/well (MCF10AT1). After 48 hours, a scratch was made with a sterile 10 µL pipette 
tip. Complete media was replaced with serum-free media, to inhibit cell growth. 
Scratched area was then imaged by phase contrast microscopy. The scratch closure was 
imaged at 3, 6, 9, 12, and 26 hours in cells expressing either EV or shRunx2.   
 
2.8.3 Cell Migration and Invasion 
Cellular migration and invasion properties were examined to measure the effects 
of Runx2 knockdown in both MCF10AT1 and MCF10CA1a cells. Corning® BioCoatTM 
Matrigel® Invasion Chambers and Control Inserts, 24-Well, 8.0 micron, plates were used 
for this assay. Matrigel is a 3D gel basement membrane-like extract that supports 
morphogenesis, differentiation, and tumor growth (Kleinman & Martin, 2005).  Matrigel 
invasion chambers were thawed to room temperature, rehydrated for two hours in 
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DMEM and 0.1% BSA before cells were plated in the insert at 50,000 cells/insert in 
DMEM and 0.1% BSA. Chemoattractant (complete media, as described above) was 
added to the well, outside the insert. After 18-24 hours, cells inside the chamber were 
removed by scraping with cotton-tipped applicators, inserts were washed in PBS, then 
fixed with ice cold methanol for 20 minutes, allowed to air dry for 30 minutes, stained 
with crystal violet for 20 minutes, and imaged using a Leica M165FC dissecting 
microscope equipped with a color camera.  
 
2.9 Next Generation RNA Sequencing 
 Next-generation RNA sequencing is a recent development that has improved gene 
expression studies. Sequence-based methods for analysis of the global transcriptome have 
allowed alternative splicing isoforms to be identified, transcript fusions to be detected, as 
well as the identification of strand specific expression (Dillies et al., 2013). It can also be 
used to detect differential expression of genes between different tissues or conditions. It 
is ideal for detection of low expressing genes and can cover the entire transcribed portion 
of the genome (Dillies et al., 2013; Morozova & Marra, 2008). Next generation 
sequencing provides genome-wide information of the levels of gene expression, structure 
of the gene loci, and any sequence variation that is present (Morozova & Marra, 2008). 
This is a more precise and comprehensive alternative to microarrays and Sanger 
sequencing. Microarrays are a hybridization-based method that is not capable of fully 
examining a genome due to the many types and levels of RNA (Ozsolak & Milos, 2011). 
Next generation RNA sequencing does have limitations, especially for certain 
applications such as single strand transcription analysis, as strand switching may occur 
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during cDNA synthesis. Other biases may occur such as transcript-length bias, and biases 
at steps such as priming with random hexamers, ligations, or cDNA synthesis (Ozsolak & 
Milos, 2011). 
 RNA was isolated as described above. We used the TruSeq Stranded Total RNA 
Library Prep kit with Ribo-Zero Gold (Illumina, San Diego, CA, USA) to create the RNA 
library used for sequencing at the University of Vermont Advanced Genome 
Technologies Core Facilities Massively Parallel Sequencing Facility to sequence RNA 
samples infected with EV or shRunx2 in both MCF10AT1 and MCF10CA1a. Next, using 
the Kappa Real-Time Library Amplification Kit (Kapa Biosystems, Wilmington, MA, 
USA) DNA was amplified further. The library was quantified using the Qubit dsDNA HS 
Assay Kit (Thermo Fischer Scientific) and analyzed using Bio-analyzer (Agilent 
Technologies, Santa Clara, CA, USA) before being sequenced as single-end 100 bp reads 
(IlluminaHiSeq1000, UVM Advanced Genome Technologies Core). Sequence files 
(fastq) were mapped to the most recent human genome assembly (hg38) (PMID: 
23104886). Expression counts were determined by HTSeq using gene annotations 
(Gencode v25) and differential expression by DESeq2. Data was then assessed by 








CHAPTER 3: RESULTS 
3.1 Runx2 levels can be decreased by both shRNA and CRISPRi methods 
Runx2 levels were measured using qPCR as well as Western blot to validate 
shRNA lentiviral knockdown of Runx2. Figure 9 demonstrates by qPCR that in 
MCF10CA1a and MCF10AT1 cells Runx2 levels post-sort were depleted by 50%, *p= 
0.001804 and 80%, *p=0.018803, respectively. Western blot densitometry analysis 
shows that Runx2 was reduced about 60% in both MCF10AT1 and MCF10CA1a, 
*p=0.008, and *p=0.0046, respectively. Runx1 levels were also measured because Runx1 
and Runx2 have been reported to have a reciprocal relationship in MDA-MB-231 and 
MCF7 breast cancer cell lines (Cohen-Solal, Boregowda, & Lasfar, 2015). However, 
analysis of Runx1 at both RNA and protein levels in cells with shRunx2 showed no 
significant difference upon depletion of Runx2 in this cell model. We observed 
significant knockdown of Runx2 on both RNA and protein levels in the shRUNX2 cells 




Figure 9: Validation of Runx2 knockdown in MCF10AT1 and MCF10CA1a using 
shRNA A. Knockdown Runx2 mRNA in MCF10AT1 and MCF10CA1a shRunx2 versus 
empty vector cells. Paired, two-tailed t test *p value <0.05, **p <0.01 for empty vector versus 
shrunx2. CT= Threshold cycle. B. Western blot of Runx2 and Runx1 expression in empty 
vector versus shRunx2 MCF10AT1 and MCF10CA1a. C. Densitometry of Runx2 and Runx1 







3.2 Runx2 knockdown decreases the expression of mesenchymal markers in 
premalignant MCF10AT1 cells 
We tested the hypothesis that Runx2 knockdown decreased mesenchymal 
properties of the cells, while increasing epithelial characteristics. Runx2 targets including 
Vimentin, N-cadherin, E-cadherin, Fibronectin, VEGF, and IL-8 were identified to study 
the effect on molecular markers of EMT (Pratap et al., 2009; Pratap et al., 2006; Pratap et 
al., 2008). Other targets, including Survivin, ITGB1, and ITGA3, were chosen from RNA 
sequencing datasets based on their involvement in avoiding apoptosis and cell-to-cell 
contact. Expression levels of EMT markers including the epithelial marker E-Cadherin, 
and the mesenchymal markers N-Cadherin, Fibronectin, ITGA3, ITGB1, and Vimentin 
were measured (Figure 10). Although not statistically significant, there is a general trend 
towards decreased RNA expression of mesenchymal markers. The epithelial marker, E-
cadherin, as well as the two integrins, did not change. Since integrins are secreted 
proteins, their secreted levels may have changed, but overall RNA levels did not. Western 
blot densitometry to evaluate protein levels showed that the epithelial marker E-Cadherin 
does not change, while there is a slight decrease in both mesenchymal markers, N-






Figure 10: Decreased expression of EMT markers due to Runx2 knockdown in MCF10AT1. A. qPCR 
showing the expression levels of various epithelial and mesenchymal markers. B. Other Runx2 targets that 
contribute to EMT also decreased in response to Runx2 knockdown. C. Western blot of some epithelial and 
mesenchymal proteins. D. Densitometry of Western blots. 
 
3.3 Proliferation rate is not affected by knockdown of Runx2 in MCF10AT1 
Previous studies have shown that in various late-stage breast cancer cell lines, 
knockdown of Runx2 decreases tumor-forming capabilities (Pratap et al., 2009). We 
decided to test whether tumor-related proliferation characteristics were inhibited by 
Runx2 knockdown in both MCF10AT1 and MCF10CA1a cell lines. In MCF10AT1, 
	 	32	
there was not a significant difference in proliferation rates between EV and shRunx2 cells 
(Figure 11). Although untreated MCF10AT1 parental cells showed slightly slower 
proliferation rates than the EV and shRunx2 cells, it was not statistically significant.   
 
 
Figure 11: Proliferation rate in MCF10AT1 is not affected by Runx2 knockdown. p >0.05. This is 
based on three biological replicates, counted in triplicate for four days. 
 
3.4 Migration as measured by a scratch assay is not affected by Runx2 knockdown 
 Migration is an important step in metastasis because cancer cells must be able to 
sense and respond to chemical signals to lead them to a suitable environment in which to 
grow (Kozlow & Guise, 2005). One property of cancer cells is increased migration 
capabilities, leading to increased tumorigenesis. In the parental MCF10A cell lines, 
overexpression of Runx2 activates migration and invasion pathways through matrix 
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metalloprotease (MMP)-2, MMP-9, and osteopontin (Pratap et al., 2009). As described 
by Pratap et al., 2009, knockdown of Runx2 in triple-negative breast cancer cells 
abrogates a tumor phenotype. We investigated effects of Runx2 knockdown on cell 
migration in the MCF10AT1 and MCF10CA1a cell lines that represent premalignant and 
metastatic breast cancer cells derived from MCF10A cells. Runx2 knockdown did not 
appear to affect migration rate in MCF10AT1 (Figure 12). 
 
 
Figure 12: Runx2 knockdown does not affect cell migration in MCF10AT1. A. Representative images 
of scratch closure in EV versus shRunx2 at 0 and 26 hours after the scratch was made B. Graph showing 
percent closure of the scratch over time for both EV and shRunx2 MCF10AT1 cells, completed in three 




3.5 Migration and invasion as measured by a Matrigel assay were not affected in 
MCF10AT1 when Runx2 was depleted 
 We measured both migration and invasion by using the Corning Matrigel 
Transwell Assay. These come with Matrigel coated inserts and non-Matrigel coated, or 
control inserts. The control inserts consist of a wire mesh that allows cells to demonstrate 
their migration capabilities. The Matrigel insert has the same mesh, but also a layer of 
Matrigel, which is used to measure invasion capabilities. Since Runx2 is known to 
upregulate genes involved in migration and invasion (Pratap et al., 2009), we assessed 
migration and invasion capabilities of Runx2 knockdown compared to EV cells. Runx2 





































Figure 13: Runx2 knockdown does not alter migration and invasion capabilities in MCF10AT1. A. 
Representative images of invasion and migration chambers in the Matrigel Transwell Assay. B. Optical 
density of n=3 biological replicates for invasion and migration in both EV and shRunx2, p>0.05. 
 
3.6 Runx2 knockdown affects the expression of both mesenchymal and epithelial 
markers in MCF10CA1a 
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Runx2 is a transcription factor for various genes involved in EMT. We measured 
the levels of some of the genes associated with EMT in response to Runx2 knockdown to 
determine if Runx2 influenced the expression of these genes directly. In the MCF10CA1a 
cells, the epithelial marker, E-cadherin, and the mesenchymal markers, N-cadherin, 
fibronectin, ITGA3, ITGB1, and vimentin, decreased by qPCR. We also measured the 
protein levels using Western blot, which confirms the qPCR results. E-cadherin protein 
levels decreased significantly as shown by Western blot densitometry (Figure 14) when 
Runx2 knockdown occurs. However, the changes in vimentin and N-cadherin between 
















Figure 14: Runx2 knockdown changes expression level of Runx2 target genes in MCF10CA1a. A. 
qPCR of epithelial and mesenchymal markers shows a general decrease in expression levels in shRunx2 
cells compared to EV, paired, two-tailed t test, p>0.05. B. Additional Runx2 target gene expression levels 
measured by qPCR. C. Representative Western blots of an epithelial and two mesenchymal markers. D. 
Densitometry on Western blots. For E-cadherin, n=5 and *p <0.01. 
 
3.7 Runx2 knockdown did not change the proliferation rate in MCF10CA1a 
To determine if knocking down Runx2, a tumor promoter, affects proliferation, 
MCF10CA1a cells were counted daily for four days to determine proliferation rate. There 
was no significant difference between proliferation rates of empty vector and shRunx2 












Figure 15: Runx2 knockdown does not affect MCF10CA1a proliferation rates. p >>0.05, three 
biological replicates, each counted in triplicate. 
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3.8 Migration rate is slightly increased by Runx2 knockdown in MCF10CA1a 
The migration rate as measured by scratch assays was determined to evaluate the 
effect of Runx2 knockdown on migration properties of MCF10CA1a cells, since it 
decreased various proteins involved in the epithelial to mesenchymal transition. Although 
not significant (p=0.078), Runx2 knockdown marginally increased the migration rate of 
shRunx2 cells compared to EV, as measured by percent closure of scratches (Figure 16).  
 
 
Figure 16: Runx2 knockdown slightly alters migration rate in MCF10CA1a. A. Percent closure over 
time in the EV versus shRunx2 MCF10CA1a cells, p=0.078, n=6 from three biological replicates. B. 
Representative images of scratches at 0 hours and 26 hours in EV and shRunx2. 
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3.9 Migration and invasion capabilities are not altered by Runx2 knockdown in 
MCF10CA1a 
As Runx2 is a tumor promoter, knocking down Runx2 may alter the ability of 
these cells to migrate and invade. Although Runx2 knockdown decreased the expression 
of various mesenchymal genes involved in EMT on an RNA level, migration and 
invasion properties of these cells as measured by Matrigel Transwell Assay were not 



































Figure 17: Runx2 knockdown does not alter migration and invasion capabilities in MCF10CA1a. A. 
Representative images of the invasion and migration Matrigel Transwell Assays in EV and shRunx2. B. 
Optical density from three biological replicates, p >0.05. 
 
3.10 Next Generation RNA sequencing analysis of EV and shRunx2 expressing cells 
 RNA sequencing can identify genes that are differentially expressed and may be 
contributing to a cell’s cancer phenotype (Langmead, Hansen, & Leek, 2010; P. Liang et 
al., 1992). The identification of differentially expressed genes between the EV and 
shRunx2 cell lines can lead to the identification of novel pathways that may be regulated 
by Runx2. We encountered a few problems when completing the RNA sequencing 
analysis. Figure 18 is a Principal Component Analysis (PCA) plot of RNA sequencing 
datasets that shows variation in global RNA expression between samples, courtesy of 
Coralee Tye. The PCA analysis of our datasets from both MCF10AT1 and MCF10CA1a 
showed no significant changes in global RNA expression. This is a problem because the 
change in global RNA expression in shRunx2 cells should be significantly different than 
that in the EV cells. Further analysis using DEseq revealed no significantly changed 
RNAs between MCF10CA1a EV and shRunx2 expressing cells and only 25 differentially 
expressed RNAs between MCF10AT1 EV and shRunx2 expressing cells. To investigate 
this unexpected result, we included RNA sequencing data from untreated MCF10AT1 
and MCF10CA1a cells and reanalyzed all datasets using PCA and reviewed RUNX2 
RNA sequencing read counts between untreated, EV, and shRunx2 cells. Our data 
revealed that EV and shRunx2 expressing cells grouped closer to each other compared to 
the untreated cells by PCA analysis (Figure 18). Furthermore, EV expressing cells 
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seemed have Runx2 transcript levels similar to shRunx2 expressing cells (data not 
shown). Because of similar alterations in RUNX2 RNA levels in EV versus shRunx2 
cells, further analysis was not possible. We think this discrepancy could be resolved in 
















Figure 18: Principal Component Analysis (PCA) of RNA sequencing using next generation 
sequencing. A. PCA plot of global MCF10AT1 RNA sequencing data. B. PCA plot of global MCF10CA1a 
RNA sequencing data. 
 
3.11 Inducible Knockdown of Runx2 using the CRISPRi system 
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We used an inducible CRISPRi system as an alternative method to knock down 
Runx2. First, MCF10AT1 and MCF10CA1a cells were transfected with dCas9-KRAB, a 
catalytically dead nickase. After selection with G418, cells were induced with 
doxycycline. dCas9 protein was detectable by Western blotting (Figure 6). Then, cells 
were infected with one or both guide RNAs designed to target Runx2 at promoter 1 and 
promoter 2. We tested whether the induction caused decreased Runx2 levels by Western 




Figure 19: CRISPRi knockdown of Runx2. Western blot of Runx2 expression in dCas9/guide and 











CHAPTER 4: DISCUSSION 
 In this study, we show that Runx2 knockdown influences expression of genes 
involved in the epithelial to mesenchymal transition in both MCF10AT1 and 
MCF10CA1a. This is supported by qPCR and Western blot data showing that 
knockdown of Runx2 decreases the expression of N-cadherin, Fibronectin, and Vimentin. 
These genes are involved in making cancer cells more mesenchymal, which is an 
important step in the EMT process involved in metastasis. Supporting these observations, 
in normal mammary epithelial cells, aberrant Runx2 overexpression promotes EMT-like 
changes and disrupts normal breast epithelial structure (Akech et al., 2010). Additional 
Runx2 targets that may play a role in tumorigenesis are Survivin, IL-8, and VEGF. 
Survivin inhibits apoptosis and mitosis regulation, VEGF is involved in angiogenesis, 
and IL-8 is involved with initial colony growth as well as apoptosis resistance (Hartman 
et al., 2013; Span et al., 2004). Both Survivin and IL-8 decreased slightly in response to 
Runx2 knockdown. One other target we measured was PTHrP. PTHrP is involved in 
activating osteoclasts, which in turn, allows breast cancer cells to survive in bone (Boras-
Granic & Wysolmerski, 2012). Runx2 activates genes such as PTHrP, making it an 
important mediator of interactions between bone and breast cancer cells when they 
metastasize to bone (Chen, Sosnoski, & Mastro, 2010). However, our results did not 
show a difference in PTHrP expression between EV and shRunx2 cells. 
  In addition to promoting a mesenchymal phenotype, overexpression of Runx2 in 
MCF10A cells causes an increase in proliferation and a loss of basement membrane 
formation compared to control (Pratap et al., 2009). To test if this was also true in our 
model, a proliferation assay was performed. In MCF10AT1 and MCF10CA1a, 
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knockdown of Runx2 did not seem to affect the proliferation rate significantly. 
MCF10CA1a shRunx2 cells proliferated slightly slow than EV cells, however the 
difference was not significant. One explanation for why these results contradict previous 
data that show Runx2 knockdown changes functional aspects of other breast cancer cell 
lines could be the effects of the EV in our system. In addition, the effect of RUNX2 
knockdown has not been studied in this MCF10A progression series, where Runx2 levels 
are already low compared to other triple-negative breast cancer cell lines, such as MDA-
MB-231. It is possible that levels are already too low, so knocking them down does not 
significantly affect functional characteristics of these cells. 
Runx2 is known to directly mediate migration and invasion by activating MMPs 
and osteopontin in some cancer cell types (Akech et al., 2010). It also regulates the pro-
angiogenic factor VEGF, indicating that Runx2 may have a role in promoting the early 
events in breast cancer (Akech et al., 2010). This raises the hypothesis that Runx2 
knockdown may inhibit invasion and migration in these cells. Since the mesenchymal 
markers we tested decreased, and VEGF also decreased, we decided to test if migration 
of these cells was inhibited. Scratch migration assays are a useful way of measuring 
migration in a culture that mimics epithelial conditions (C. C. Liang et al., 2007). 
Another method of measuring both migration and invasion is to use the Matrigel 
chambers. Each Matrigel-coated chamber measures invasion. The more cells that can 
pass through the Matrigel matrix, the better ability they have to invade. Since knocking 
down Runx2 decreases levels of mesenchymal genes including N-cadherin, Vimentin, 
and Fibronectin, which help regulate the invasion and migration process, we expected 
that there would be less invasion and migration in the Runx2 knockdown cells. However, 
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there was not a difference between the EV and shRunx2 in MCF10AT1 or MCF10CA1a 
in terms of migration or invasion capabilities of these cells. Since these cells represent 
premalignant and metastatic cells with relatively low levels of Runx2, Runx2 regulation 
may be different than in the highly metastatic MDA-MB-231 cells.    
 We also investigated the effects of Runx2 knockdown on global RNA expression 
in both MCF10AT1 and MCF10CA1a using RNA sequencing. A relatively new 
application of RNA sequencing is the ability to quantify gene expression based on the 
number of mapped reads (Tarazona, Garcia-Alcalde, Dopazo, Ferrer, & Conesa, 2011). 
We hoped to identify differentially expressed genes between the EV and shRunx2 
expressing MCF10AT1 cells, representative of a less aggressive cancer. These 
differentially expressed genes could be used to identify novel pathways controlled by 
Runx2 in cancer progression. However, due to non-specific effects observed in the EV 
control, our RNA sequencing data could not be analyzed further. In Figure 18, on the left 
hand side of the PCA plot, the three untreated replicates of the parental MCF10AT1 or 
MCF10CA1a cells cluster together very closely. We would expect that the EV expressing 
cells would group closer to the untreated cells than the shRNA cells. However, the EV 
and shRunx2 sample pairs grouped together in PCA, indicating variation between 
biological replicates. The other problem is the effect of the EV on Runx2 transcript levels 
that is almost comparable to that of shRunx2. This EV and shRNA were used in 
published data (Pratap et al., 2009), but in the MDA-MB-231 cells, where the effect of 
the EV was less drastic. However, in our system, EV effects prevented further analysis of 
the RNA sequencing data. A different empty vector or scramble shRNA control could be 
used to avoid this in the future.  
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We also developed an alternative method to knockdown Runx2 using CRISPRi. 
This method has advantages over shRNA-mediated knockdown because Runx2 
knockdown can be modulated by an inducible system. This allows control over the level 
of Runx2 knockdown, and can be reversed if necessary. Future directions include 
characterization of the Runx2 knockdown in these cells. Since the effects of doxycycline 
seem to disappear by the 48 hour mark (Figure 19), dCas9/Guide cells were re-induced 
with doxycycline every 24 hours for up to 72 hours and show a time dependent decrease 
of Runx2 protein levels is possible (data not shown). Once the characterization of the 
Runx2 knockdown of these cells is complete, they can be used to repeat the functional 
assays to investigate the effects of Runx2 knockdown in the MCF10A series, without the 














CHAPTER 5: CONCLUSION 
 Runx2 has been shown to play a role in promoting the early stages of breast 
cancer, as well as later, metastatic stages by changing the expression of various genes 
(Barnes et al., 2004; Pratap et al., 2009; Pratap et al., 2006). Our results indicate that 
Runx2 knockdown decreases the expression of various mesenchymal markers, such as N-
cadherin, Fibronectin, and Vimentin in MCF10AT1 and MCF10CA1a breast cancer cells. 
However, we did not find a difference in functional characteristics or in RNA sequencing 
of EV versus shRunx2 cells, possibly due to nonspecific effects of EV on Runx2 levels. 
We need to reevaluate our data using a different EV control. Alternatively we could use 
other methods of Runx2 knockdown, such as CRISPRi dCas9 cells we developed against 
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